An update to my column yesterday about Aerie Pharmaceuticals (AERI) and what I called an under-appreciated manufacturing risk related to its glaucoma drug Rhopressa, now under review at the FDA.

It now looks like I over-appreciated the Rhopressa manufacturing challenge.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Get rid of short shill Adam FEURSTEIN Or lose business

    This guy is a known basher of great companies
    He’s a shill for short hedge funds

    Why didn’t you check his background?

    STAT better be smart

    You guys are gonna lose subscribers

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy